Kestra Medical Competitors
| KMTS Stock | 19.10 -0.46 -2.35% |
Kestra Medical vs Evotec SE Correlation View
Very weak diversification
KMTS currently posts a 0.5 correlation with EVO, indicating a Very weak diversification relationship for the active sample. The overlap area represents the portion of risk that may be diversified away when both instruments are held together and nothing else in the portfolio changes.
Moving together with Kestra Stock
Moving against Kestra Stock
The degree to which Kestra Medical's exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
Kestra Medical Competition Correlation Matrix
Correlation analysis between Kestra Medical Technologies and its competitors provides context for understanding whether diversification is real or only superficial inside the same peer group. A reading near +1 usually means prices have moved in tandem, a reading near -1 suggests opposite movement, and a reading near zero points to weaker historical dependence.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Strong stock returns do not always mean Kestra Medical Company is outperforming its peers on a fundamental level. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kestra Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AZTA | 2.32 | -0.64 | 0.00 | -0.61 | 0.00 | 3.76 | 29.88 | |||
| NVCR | 3.28 | 0.17 | 0.02 | 0.00 | 4.20 | 6.04 | 36.05 | |||
| STAA | 2.37 | -0.42 | 0.00 | 2.67 | 0.00 | 4.66 | 14.49 | |||
| BLFS | 2.21 | -0.24 | 0.00 | -0.29 | 0.00 | 3.92 | 18.09 | |||
| WVE | 2.81 | -0.31 | 0.00 | -0.35 | 0.00 | 4.41 | 21.76 | |||
| PLSE | 3.90 | 1.31 | 0.21 | 0.23 | 3.77 | 7.62 | 66.16 | |||
| NEOG | 2.11 | 0.47 | 0.20 | 1.37 | 2.20 | 3.71 | 40.83 | |||
| TERN | 2.30 | 0.20 | 0.10 | 1.05 | 2.72 | 5.15 | 14.31 | |||
| PGEN | 3.72 | 0.03 | 0.00 | -0.08 | 0.00 | 7.01 | 18.66 | |||
| EVO | 2.68 | -0.11 | 0.00 | -0.18 | 0.00 | 5.02 | 22.70 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Kestra Medical financial statement analysis. It represents the amount of money remaining after all of Kestra Medical Technologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Kestra Medical and related stocks such as Azenta Inc, Novocure, and STAAR Surgical Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZTA | 1.5 M | 136.8 M | -2.2 M | 4.5 M | 14.2 M | -69.5 M | 62.6 M | 116.6 M | 28.8 M | 64.9 M | 110.7 M | -429 M | -14.3 M | -164.9 M | -55.8 M | -64.1 M | -67.3 M |
| NVCR | -77.4 M | -77.4 M | -77.4 M | -77.4 M | -80.7 M | -111.6 M | -131.8 M | -61.7 M | -63.6 M | -7.2 M | 19.8 M | -58.4 M | -92.5 M | -207 M | -168.6 M | -136.2 M | -143 M |
| STAA | -3.8 M | 1.3 M | -1.8 M | 398 K | -8.4 M | -6.5 M | -12.1 M | -2.1 M | 5 M | 14 M | 5.9 M | 27.5 M | 39.7 M | 21.3 M | -20.2 M | -80.4 M | -76.4 M |
| BLFS | -500 K | -2 M | -1.7 M | -1.1 M | -3.2 M | -4.2 M | -6.9 M | -2.5 M | 3.3 M | -1.7 M | 2.7 M | -8.9 M | -139.8 M | -66.4 M | -20.2 M | -12.1 M | -12.7 M |
| WVE | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -5.2 M | -19.2 M | -55.4 M | -102 M | -146.7 M | -193.6 M | -149.9 M | -122.2 M | -161.8 M | -57.5 M | -97 M | -204.4 M | -194.2 M |
| PLSE | -474.9 K | -474.9 K | -474.9 K | -474.9 K | -474.9 K | -2.8 M | -9.5 M | -25.6 M | -37.5 M | -46 M | -49.7 M | -63.2 M | -59 M | -42.2 M | -53.6 M | -72.8 M | -69.1 M |
| NEOG | -1.1 M | 22.5 M | 27.2 M | 28.2 M | 33.5 M | 36.6 M | 43.8 M | 63.1 M | 60.2 M | 59.5 M | 60.9 M | 48.3 M | -22.9 M | -9.4 M | -1.1 B | -982.8 M | -933.7 M |
| TERN | -17.7 M | -17.7 M | -17.7 M | -17.7 M | -17.7 M | -17.7 M | -17.7 M | -17.7 M | -17.7 M | -68.8 M | -29.4 M | -50.2 M | -60.3 M | -90.2 M | -88.9 M | -80 M | -84 M |
| PGEN | -85.3 M | -85.3 M | -81.9 M | -39 M | -81.8 M | -84.5 M | -186.6 M | -117 M | -509.3 M | -170.5 M | -170.5 M | -92.2 M | 28.3 M | -95.9 M | -126.2 M | -113.6 M | -119.3 M |
| EVO | -12.8 M | 6.7 M | 2.5 M | -25.4 M | -7 M | 16.5 M | 27.5 M | 24.3 M | 84.2 M | 38.2 M | 6.3 M | 215.5 M | -175.7 M | -83.9 M | -196.1 M | -176.5 M | -167.6 M |
Kestra Medical Competitive Analysis
Placing Kestra Medical next to Azenta, Novocure, and STAAR Surgical puts raw numbers into competitive context. A 1.14 B valuation paired with 59.8 M in revenue sets the baseline. Profitability is a concern, with a -172.99% net margin and -92.65% return on equity signaling pressure on earnings. Azenta converts shareholder equity more efficiently at 1.53% versus Kestra Medical at -92.65%. Top-line revenue favors Novocure by a wide margin: 655.4 M to 59.8 M. Net profitability gives STAAR Surgical an edge at -33.60% versus Kestra Medical at -172.99%.| Better Than Average | Worse Than Peers | View Performance Chart |
Kestra Medical Competition Peer Performance Charts
How to Analyze Kestra Medical Against Peers
Kestra Medical's peer analysis compares Kestra Medical with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Kestra Medical trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Kestra Medical leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Competitor benchmarking for Kestra Medical often reveals which operating metrics are genuinely differentiated and which appear similar across the peer group. Short interest comparison for Kestra Medical and its peers can highlight which companies attract the most skepticism from market participants. Competition analysis adds context to price action by grounding it in relative fundamentals. For peer comparison, Kestra Medical has a market cap of 1.14 B, profit margin of -1.73%.
Unless otherwise specified, data for Kestra Medical Technologies is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day.